

Global Vaccine and Immunization Research Forum 2023

Grand Hyatt, Incheon, Republic of Korea

28 – 30 March 2023

Mucosal Immunity

*What's special about it and
can vaccines induce it?*

Peter Openshaw

National Heart and Lung Institute, Imperial College London



P_Openshaw

p.openshaw@imperial.ac.uk


Seasonal and pandemic influenza: 100 years of progress

Jake Dunning, Ryan S. Thwaites, Peter J.M. Openshaw

- **About 75% of all lymphocytes are mucosal**
- Viral entry into the respiratory epithelium is blocked by specific mucosal antibody, mucus and antimicrobial proteins.
- Inflammatory mediators produced locally, influenced by genetic factors, environment and local exposure history
- Innate immune responses by airway cells, macrophages, and NK cells impede viral replication
- T-cell responses are involved in viral clearance


<https://doi.org/10.1038/s41385-020-0287-5>

<https://www.sciencedirect.com/science/article/pii/S1933021922003233?via%3Dihub>



Seasonal and pandemic influenza: 100 years of progress, still much to learn

Jake Dunning¹, Ryan S. Thwaites² and Peter J. M. Openshaw¹



A spatially resolved atlas of the human lung characterizes a gland-associated immune niche

[Elo Madisson, Amanda J. Oliver, ... et al Kerstin B. Meyer](#)
[Nature Genetics](#) 55:66–77 (2023)


nature genetics

Profiled 5 proximal-to-distal locations of healthy human lungs using multi-omic single cell/nuclei and spatial transcriptomics (lungcellatlas.org)

Identified 80 cell types/states from >190,000 cells including 11 new cell types

Discovered new anatomical compartment: epithelial, vascular, stromal and nerve bundle micro-environment with novel peribronchial fibroblasts, providing a **survival niche for IgA plasma cells in the airway submucosal glands (SMG).**

This 'gland-associated immune niche' promoting longevity and antibody secretion locally through expression of CCL28, APRIL and IL-6.



See comment: <https://www.nature.com/articles/s41588-022-01244-3>

<https://www.nature.com/articles/s41588-022-01243-4.pdf>

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

[Ryan S Thwaites et al](#)

The methods of nasal absorption using synthetic absorptive matrices (SAM) to absorb the mucosal lining fluid of the human respiratory tract.

- Non-invasive technique
- Absorbs fluid from the inferior turbinate
- Causes minimal discomfort.
- Yields reproducible results
- Allows frequently repeat sampling



[Download](#) video file. (106M, mp4)


<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908664/>

LAIV Challenge



- Use LAIV as a human challenge agent in young adults to study:
 - Viral shedding
 - Effect of pre-existing immunity: humoral and cellular
 - The innate response to LAIV: association with generation of immunity
 - **The (mucosal) humoral immune response to LAIV**



Dr Ryan Thwaites






Study design: n=40 healthy 18-30 y.o.



Dr Ryan Thwaites

No screening criteria (“all-comers” approach)


Viral shedding



- Shedding not observed for A viruses (but there is an antibody response...)
- Quantity of B virus shedding unrelated to the scale/nature of antibody response



Antibody response: Compartmentalisation



Little overlap between plasma IgG and nasal IgA responses – often one or the other



Dr Ryan Thwaites

Summary of LAIV Ab findings

- Response in plasma HAI only in those with low baseline titres
- Antibody response more frequent in nasal samples than plasma
- **Antibody responses in nasal and plasma are independent**

ISARIC preparedness platform



Kenny Baillie


- Developed in the wake of the flu pandemic
- Uses WHO-approved clinical data tool from MOSAIC
- Sleeping platform, launched 2011
- Pre-agreements in place with >200 UK hospitals



Calum Semple



BILL & MELINDA
GATES foundation





Peter Openshaw



Kenny Baillie



Calum Semple




**Hospitalized
COVID-19
patients recruited**

- Tier 0**
- Demographic data
 - Outcome
 - Comorbidities

- Tier 1**
- Single sample set:
- Plasma/serum
 - Nasal swabs
 - Urine + Stool

- Tier 2**
- Serial biological sample sets

446 participants




226 patients ISARIC and PHOSP
127 patients PHOSP
(convalescent only)
93 patients from ISARIC only
(acute only)

6 to 9 month visit:
Median: 16th March 2021
(September 2020 to August 2021)

>12 month visit:
Median: 11th July 2021
(March 2021 to March 2022)




Dr Felicity Liew




February 2020 to
March 2021

Prior to emergence
of Omicron variant
(November 2021)







356 Nasosorption samples 

569 Plasma samples 

Clinical data: vaccination,
persistent symptoms


Nasal IgA is not affected by vaccination, nasal IgG mirrors plasma



The nasal IgA response is compartmentalized after vaccination


93% vaccinated

6 month



12 month

95% vaccinated



Response
█ Plasma
█ Nasal

Upper airway and brain protection by plasma cells: A local affair

Rebecca Cornelis¹ and Ziv Shulman^{1,*}

¹Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel

*Correspondence: ziv.shulman@weizmann.ac.il

<https://doi.org/10.1016/j.immuni.2022.10.012>

VOLUME 55, ISSUE 11, P1972-1974, NOVEMBER 08, 2022

A mucosal barrier protects the brain from viral invasion through the olfactory mucosa

This barrier restricts the passage of circulating antibodies into the mucosa

Specialised plasma cells are present in a mucosal niche; these prevent viral infection of the airways and the brain through local antibody production.

<https://doi.org/10.1016/j.immuni.2022.10.012>




Figure 1. Plasma cells are recruited to olfactory mucosa and secrete protective antibodies that provide local protection from respiratory viral infections

Imperial College
London



£3m, 5 year Medical Research Council/Wellcome-funded network to:

Support, develop and advocate the use of human infection challenge, to...

- improve understanding of infections, and the diseases they cause
- enhance the development of new/better vaccines/treatments for infections of global importance

Imperial College
London



First SARS-CoV-2 challenge study

Clinical design and recruitment


- Extensive public support & interest: ~27,000 on-line registrations
- Before vaccines were available
- Screening+++:
healthy, seronegative,
willing & able



Nature Medicine 28:1031–1041 (2022)





Chris Chiu



Local mediator response, systemic T cells

COVID-19 Human Challenge: Infected vs Uninfected



Days since challenge: -1



Summary of events in primary SARS-CoV-2 infection



Chris Chiu



Systemic immunity is great at preventing systemic illness

- It is well induced by intramuscular vaccines
- Can be long-lived

Mucosal immunity is necessary for local protection

- Controlled separately from systemic immunity
- Induced by mucosal vaccines and by local infection
- Typically lasts only a few months (unless boosted)

How can mucosal responses be induced to control transmission?